Houston, TXNCT06207305Now EnrollingIRB Ready

Metastatic Appendiceal Adenocarcinoma Clinical Trial in Houston, TX

Access cutting-edge metastatic appendiceal adenocarcinoma treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access metastatic appendiceal adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic appendiceal adenocarcinoma treatment provided free

Apply for This Houston Location

Check if you qualify for this metastatic appendiceal adenocarcinoma clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Metastatic Appendiceal Adenocarcinoma Study in Houston

To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Age 18 years and above. There will be no upper age restriction
ECOG performance status ≤ 2
Participants must have histologically confirmed diagnosis of unresectable locally metastatic appendiceal adenocarcinoma
Metastatic disease in the peritoneal cavity and not a candidate for cytoreductive surgery
Participants must have adequate organ and marrow function as defined below: leukocytes ≥3000/mcL absolute neutrophil count ≥1,500/mcL platelets ≥75,000/mcL total bilirubin ≤ institutional upper limit of normal (ULN) creatinine ≤ 1.5X institutional ULN
For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Participants with metastases outside the peritoneal cavity are not eligible for enrollment
Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
The effects of PTX on the developing human fetus are unknown. For this reason, and because Taxane agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable

Exclusion Criteria

ary factor which may be one of the following:
Postmenopausal (no menses in greater than or equal to 12 consecutive months)
History of hysterectomy or bilateral salpingo-oophorectomy
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)
History of bilateral tubal ligation or another surgical sterilization procedure Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of paclitaxel administration.
Ability to understand and the willingness to sign a written informed consent document 14\) English and non-English-speaking participants Exclusion Criteria:
Active infection such as pneumonia or wound infections that would preclude protocol therapy
Participants with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure
Participants deemed unable to comply with study and/or follow-up procedures (i.e., cognitive impairment)
Participants with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
Previous surgery that would preclude safe diagnostic laparoscopy with port placement
Participants who have not recovered from adverse events (AE) due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia
Participants who are receiving any other investigational agents
Participants with metastases outside the peritoneal cavity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX or other agents used in study
Participants with psychiatric illness/social situations that would limit compliance with study requirements Participants who are pregnant

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06207305) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Appendiceal Adenocarcinoma Treatment Options in Houston, TX

If you're searching for metastatic appendiceal adenocarcinoma treatment options in Houston, TX, this clinical trial (NCT06207305) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic appendiceal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic appendiceal adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Houston, TX

See all pulmonary embolism clinical trials recruiting in Houston — not just this study.

Browse Pulmonary Embolism Trials in Houston →

Browse More Trials by Condition

Pulmonary Embolism TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX